Oncolytics net loss more than doubled to $9.24 million in Q1 2026

• Oncolytics Biotech posted a net loss of USD 9.24 million for the quarter ended March 31, 2026, widening from USD 4.71 million a year earlier.
• Research and development expense climbed 62.57% to USD 4.55 million, driven by higher personnel costs and startup spending for a randomized Phase 2 second-line metastatic colorectal cancer study.
• General and administrative expense more than doubled to USD 4.73 million, on higher public company-related costs tied to investor relations activity and professional fees related to the Domestication.
• Cash and cash equivalents edged up to USD 5.49 million; operating cash outflow widened to USD 7.29 million.
• Fast Track Designation was granted in 2026 for pelareorep with bevacizumab and FOLFIRI in KRAS-mutant, microsatellite-stable second-line mCRC; an open market sale agreement with Jefferies allows up to USD 75 million of common stock sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001129928-26-000033), on May 14, 2026, and is solely responsible for the information contained therein.